Even If We Win in Washington... What I Learned 90 Days After RFK's Peptide Promise
1. Capitol Hill, Tuesday
Two days ago I was sitting in a marble-walled hearing room on Capitol Hill.
Across from me, a senior staffer handling health policy for one of the most influential members of the House. Beside her, two more staffers. Beside me, leadership from the Natural Products Association.
The folder on the table was thick. Patient letters. Compounding pharmacy filings. The kind of evidence that should have moved a decision months ago.
I asked one question: Why has peptide access been stalled for 90 days?
The answer came back with the kind of vague non-commitment that tells you everything.
That's how I knew this wasn't going to fix itself.
Where The Fight Stands
On February 27, 2026, HHS Secretary RFK Jr. announced that 14 of 19 peptides classified by the FDA as banned would move back to legal compounding.
That announcement is over 90 days old. The FDA has not published the reclassification. Compounding pharmacies are still in limbo. Patients are still without access.
This is what regulatory delay looks like in practice. A promise made on television, and an indefinite pause in implementation.
The NPA has been pushing this fight since the day RFK's announcement landed. Letters. Filings. Meetings. Sustained pressure.
But pressure alone isn't enough. The administrative state moves at its own speed, and the affected patients have nothing to do except wait.
Why Washington Moves This Slowly
This isn't bad luck. It's structure.
❌ The pharmaceutical industry has been the #1 lobbying industry in Washington for over a decade. Its annual lobbying spend exceeds $380 million, more than oil and gas, more than finance, more than real estate.
❌ Federal rule-making averages 3 to 7 years from proposal to implementation. Some rules take a decade.
❌ The 19 peptides removed from compounding in 2023 have been in regulatory limbo for over two years. RFK's February 27 promise was supposed to fast-track 14 of them back. We are 90+ days in. No implementing rule. No timeline. No accountability.
When a regulatory question pits patient access against pharma margin, the asymmetry isn't subtle. It shapes which letters get answered. It shapes which staffers take the meeting. It shapes which decisions move and which sit on a shelf.
This isn't conspiracy. It's structure. The regulatory process was never built to move at the speed of patient need.
That's the wall the NPA has been pushing against. That's the wall we joined them at on Tuesday.
What I Learned in DC
Three things came out of those meetings.
-
The timeline isn't unclear because no one has the answer. It's unclear because no one is willing to put one in writing. Multiple staffers used the same phrase: "We're tracking it." Nothing more specific.
-
Constituent pressure on this issue is high enough to be noticed but not high enough to force a decision. NPA leadership confirmed what I suspected. A small but coordinated push from the right offices would unstick this.
-
Even when peptide reclassification clears the FDA, that's only legal access. It isn't complete access. Mainstream doctors aren't trained for these therapies. The compounding pharmacies can fill the prescription, but the prescription has to come from a physician who knows what to write.
That third point hit me hardest.
I left those meetings understanding that the fight in Washington is winnable. But winning Washington doesn't fix what's wrong with American healthcare.
Even If We Win
Picture the moment we win in DC.
The FDA publishes the reclassification. The 14 peptides move back to Category 1. Compounding pharmacies can legally produce them again. The headlines go up. The advocacy community celebrates.
And then what?
You go to your doctor on Monday and ask for a peptide prescription. Your doctor has never written one. They don't know the dosing protocols. They can't structure a stack. They aren't trained for it, the office isn't set up for it, and conventional medical education hasn't caught up.
So you Google. You find a clinic. You pay out of pocket. You hope it's run by someone competent.
That's the actual post-victory experience. Legal access doesn't mean available access. And mainstream healthcare has no incentive to close the gap. Big Pharma profits from the chronic disease model. Insurance reimburses for what insurance has always reimbursed for. The entire system was built for a different kind of medicine than the one your body actually needs.
The Gap Is Bigger Than Doctors
The real gap isn't just a trained doctor. It's the entire infrastructure that makes peptide therapy safe.
Three pieces have to exist:
-
A regulated compounding pharmacy that can legally produce the peptide.
-
A physician trained to prescribe it and structure the protocol.
-
Ongoing oversight from someone who can adjust the protocol if something isn't working.
And here's what happens when that infrastructure is missing:
❌ Demand doesn't disappear. It moves underground.
Right now, thousands of Americans are buying research-grade peptides online from unregulated overseas suppliers. The vials arrive from factories that have never been inspected by the FDA. No purity testing. No certificate of analysis. No clinical oversight. No follow-up. No way to know what's actually in the bottle.
People are injecting themselves with substances they can't verify, sourced from facilities they can't see, with no physician who can tell them if it's working or hurting them.
That's the real cost of the regulatory delay. Not just inconvenience. Real public health risk. And it grows every day the implementing rule stays unpublished.
But Things Are Changing
Here's the part most people don't see.
The pressure works. RFK's announcement didn't happen in a vacuum. It happened because the NPA, the compounding pharmacy associations, and tens of thousands of patient letters made it impossible to ignore the issue any longer. The pharma lobby outspent the supplement-side advocacy by orders of magnitude, and we still got 14 of 19 peptides on a path back to legal access.
That doesn't happen without sustained, organized pushback. And it tells you something important about this fight: the bureaucracy is slow, but it's not immovable.
The conversations I had this week confirmed it. The staffers handling this issue know it has momentum. They know the implementing rule isn't going to stay buried forever. They know the next round of constituent calls is already coming.
Things are changing in Washington. Not as fast as anyone wants. But the direction is right.
And while we've been pushing in DC, we've been building somewhere else.
What We're Building
For the past year, while the peptide fight ran in the background, we've been building the infrastructure that doesn't exist in conventional medicine.
Not another formula. Not another newsletter. A different kind of practice.
A practice built around the medicine that actually works, the regulated supply chain that delivers it safely, and the physician relationship that follows up with you after the protocol begins.
It's almost ready.
This isn't a hypothetical. It's not a fundraising pitch. It's what we've been quietly building while we fought in Washington.
The door opens this month.
And next week, you'll see exactly what that means.
Jose
Founder, Black Forest Supplements
PS. Comment your thoughts below. I read every one, and you’re not going to want to miss this.
